Biomarkers by Oxford Global will explore the essential criteria for validating clinical biomarkers, shedding light on the steps and challenges involved.

Here, we speak to Matthias von Herrath about Biomarkers US 2023 and some current trends in the industry concerning research and technological development.

Here, we speak to UT Southwestern’s Shuang Liang about monitoring TREM2 as a non-invasive diagnostic biomarker for NASH.

A recent FNIH study demonstrates the effectiveness of non-invasive blood tests in diagnosing non-alcoholic steatohepatitis (NASH), potentially reducing the need for invasive liver biopsies and improving NASH diagnosis.

N-of-1 trials employ individualised treatments through double-blinded, randomised sequences to determine optimal approaches and enhance patient-doctor collaboration.

While biomarkers are integral to the identification and validation of disease treatment methods, there is a disconnect between existing validation approaches and their applications in commercialisation.

While the complexities associated with identifying tumour state and coordinating an effective immunotherapeutic response are many, pioneering healthcare providers are rising to the challenge.

Biomarkers in psychiatry may have the potential to overcome the challenges associated with complications such as depression, bipolar disorder, and generalised anxiety.

ICIs – immune checkpoint inhibitors – have changed the landscape of therapeutic treatment for cancer and improved survival rates for patients with advanced malignancies. However, the wide variability in clinical response is a significant limitation to treatment.

An understanding of the complex pathologies involved in patients with neurodegenerative diseases is integral to the identification of biomarkers and potential treatment methods for individuals who suffer from Alzheimer’s, Parkinson’s, and ALS. Here, we look at the development of dedicated biomarker strategies for helping to combat neurodegeneration.

Milena Dumont Milutinovic, Senior Manager of Field Applications at Quanterix, walks through the company's ultrasensitive biomarker assay technology.

We explore some of the different applications of AI in biomarkers for cancer analysis, including in urology and the characterisation of prostate cancer.

Highly involved treatment scenarios and prognostics are required to properly assess best-practice approaches for investigating issues posed by NASH and liver cirrhosis. Surrogate biomarkers present a less invasive approach to assessing these outcomes.

The immunotherapeutic was successfully trialled in patients with endometrial cancer, the results of which Merck said it would discuss with regulatory authorities.

The FDA ‘specifically requested’ data from at least 100 patients who received a minimum 12 months’ treatment of Lilly’s drug donanemab before the approval process could progress further.

KEYTRUDA demonstrated a clinically meaningful improvement in disease-free survival in patients following surgical resection and platinum-based chemotherapy.

The move follows steps announced by the EMA and the MHRA to ensure clinical trials are more reflective of patient populations.

Understanding machine learning’s role in providing a biomarker for the neurological condition.

Cancer-related cognitive impairment in young adults found pre-treatment, study reports.

How can we better define patient-centric clinical trials within the drug development process?

Study finds predictive link between genital herpes and HIV.

The potential oncolytic applications of Salmonella ZH9 include its use in mitigating diseases such as bladder cancer, with a demonstrated therapeutic effect in cancer models.

Christopher Conn, Director of Diagnostics Strategy at Amgen, leads a Discussion Group on patient testing and engagement in biomarker clinical trials.

Discover key event highlights from Oxford Global's upcoming Biomarkers for NASH Symposium 2022.

A gene signature found in antibody-producing cells could accelerate vaccine development.

In this Commentary, we explore how non-invasive biomarkers may be used to diagnose pre-symptomatic NASH in patients without them undergoing invasive biopsies.

Archana Vijayakumar, Senior Research Scientist I of Fibrosis at Gilead, presents on understanding disease progression and therapeutic efficacy in preclinical models for NASH.

Vincent Mikol, Precision Medicine Head at Sanofi, leads a discussion on navigating the current challenges of NASH in clinical development.

Amanda Heslegrave, Senior Research Fellow at the UK Dementia Research Centre, UCL, showcases cutting-edge super sensitive immunoassay research at Biomarkers UK 2021.

Quantitative mass spectrometry offers a clinical tool for the discovery of biomarkers, which can be vital in helping to treat certain cancers. In this Commentary article, we explore the applications of mass spectrometry for the identification of triple negative breast cancer and some of the implications for future research.

Key opinion leaders from GlaxoSmithKline and Weill Cornell Medicine discuss future perspectives on neuro-organoids.

Jordi Clarimon, Lead Specialist in Fluid Biomarkers at Lundbeck, leads a discussion on ‘Fluid Biomarkers for Neurodegenerative Diseases.'

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our March Discussion Group addressing ‘Translational Biomarkers to Guide Clinical Development of CAR T-Cells’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our February Discussion Group, focusing on ‘Using Biomarkers For Clinical Development & Regulatory Approval,’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

How can the industry transform itself with improved biomarkers for clinical development? And what hurdles stand in the way? We sat down with senior representatives from Galapagos, Ohio State University, and Genentech to find out more.

Melanie Anderson, Principal Scientist at MSD, on how the pandemic has made scientists rethink clinical trials.